First Horizon Advisors Inc. Takes $47,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

First Horizon Advisors Inc. bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,765 shares of the company’s stock, valued at approximately $47,000.

Several other hedge funds have also recently bought and sold shares of the business. ARK Investment Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 200.4% during the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock valued at $203,651,000 after acquiring an additional 13,777,689 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Recursion Pharmaceuticals by 37.7% in the third quarter. Vanguard Group Inc. now owns 15,506,834 shares of the company’s stock worth $118,627,000 after buying an additional 4,247,002 shares during the period. FMR LLC raised its holdings in shares of Recursion Pharmaceuticals by 134.4% during the 3rd quarter. FMR LLC now owns 10,689,532 shares of the company’s stock valued at $81,775,000 after buying an additional 6,129,935 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Recursion Pharmaceuticals by 161.2% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company’s stock worth $90,749,000 after acquiring an additional 5,680,656 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Recursion Pharmaceuticals by 15.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,157,966 shares of the company’s stock valued at $8,858,000 after acquiring an additional 157,189 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Needham & Company LLC reissued a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. KeyCorp raised their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. Finally, TD Cowen initiated coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They issued a “market perform” rating on the stock. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $12.75.

Recursion Pharmaceuticals Trading Down 2.3 %

RXRX stock opened at $8.59 on Thursday. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.92 and a twelve month high of $16.75. The company has a market capitalization of $2.02 billion, a P/E ratio of -5.54 and a beta of 0.85. The firm has a 50 day simple moving average of $9.63 and a 200-day simple moving average of $9.26.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The business had revenue of $10.89 million during the quarter, compared to the consensus estimate of $12.37 million. On average, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current year.

Insider Transactions at Recursion Pharmaceuticals

In related news, COO Tina Marriott sold 8,000 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $14.89, for a total transaction of $119,120.00. Following the transaction, the chief operating officer now directly owns 639,982 shares in the company, valued at $9,529,331.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Recursion Pharmaceuticals news, COO Tina Marriott sold 8,000 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $14.89, for a total value of $119,120.00. Following the sale, the chief operating officer now directly owns 639,982 shares in the company, valued at $9,529,331.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $7.73, for a total value of $386,500.00. Following the completion of the sale, the chief executive officer now owns 863,524 shares in the company, valued at $6,675,040.52. The disclosure for this sale can be found here. Over the last quarter, insiders sold 352,946 shares of company stock valued at $3,485,453. 15.75% of the stock is currently owned by corporate insiders.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.